Obsidian Therapeutics
About Obsidian Therapeutics
55 articles about Obsidian Therapeutics
-
Obsidian Therapeutics Announces Appointment of William Pao,M.D.,Ph.D.,to Board of Directors 6/4/2024 Obsidian Therapeutics,Inc.today announced the appointment of William Pao,M.D.,Ph.D.,to the company’s Board of Directors as an independent member。 -
Obsidian Therapeutics Announces Additional OBX-115 Safety and Effficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology(ASCO)Annual Meeting 6/3/2024 Obsidian Therapeutics Announces Additional OBX-115 Safety and Effficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology(ASCO)Annual Meeting。 -
OBX-115in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology(ASCO)Annual Meeting 5/23/2024 Obsidian Therapeutics,Inc.today announced positive updated safety and efficacy data from its first-in-human study of OBX-115,anovel engineered tumor-derived autologous T cell immunotherapy d IL15(mbIL15), in patients with immune checkpoint inhibitor(ICI)-resistant advanced or metastatic melanoma(NCT05470283)。 -
Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer 5/8/2024 Obsidian Therapeutics,Inc.today announced the appointment of Dana Alexander as Chief Technical Officer。 -
OBX-115,its Engineered TIL Cell Therapy,for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting 4/24/2024 Obsidian Therapeutics,Inc.announced two presentations,including an oral presentation on the Phase1first-in-human study of OBX-115,anovel engineered tumor-derived autologous T cell immunotherapy armored with pharmacologically regulatable membrane-bound IL15, in patients with immune checkpoint inhibitor-resistant advanced or metastatic melanoma,at the 2024 American Society of Clinical Oncology Annual Meeting,taking place in Chicago on May31–June4。 -
Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer 4/15/2024 Obsidian Therapeutics,Inc.today announced the appointment of Jeffrey Trigilio as Chief Financial Officer,effective May12024。 -
Obsidian Therapeutics Announces Oversubscribed$160.5 Million Series C Financing to Drive OBX-115 Clinical Development 4/3/2024 Obsidian Therapeutics,Inc.,aclinical-stage biotechnology company pioneering engineered cell and gene therapies,today announced it has closed asignificantly oversubscribed$160.5 million Series C financing with atop-tier syndicate of life science investors led by new investor,Wellingn管理。 -
Obsidian Therapeutics Announces Clinical&Preclinical Presentations at the American Association of Cancer Research Annual Meeting 3/5/2024 Obsidian Therapeutics,Inc.announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115and preclinical data from our cytoDRiVE®platform demonstrating regulatable cytoTIL15signal transduction in cis and trans, as well as the ability of a single DRD to coregulate two cytokines,LIGHT and mbIL15,in tumor-infiltrating lymphocytes during the AACR Annual Meeting,which will be held April5-1024 in San Diego,CA。 -
OBX-115 Engineered TIL Cell Therapy in Advanced or Metatic Melanoma Post-Anti-PD1 Therapy 12/12/2023 Obsidian Therapeutics,Inc.announced today positive top-line results from the ongoing first-in-human,Phase1clical trial evaluating the safety and efficacy of OBX-115。 -
Obsidian Therapeutics Announces Dr.Madan Jagasia as Chief Executive Officer and Other Leadership Appointments 5/23/2023 Company also adds Dr.Parameswaran Hari as Chief Development Officer and appoints Dr.Matthew Norkunas to Board of Directors。 -
Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE®Platform and Pipeline at Society for Immunotherapy of Cancer(SITC)Annual Meeting 2022 11/7/2022 Obsidian Therapeutics,Inc.,aclinical-stage biotechnology company pioneering engineered cell and gene therapies,today announced it will present preclinical data highlighting its recentcytoDRiVE®platform and pipeline advances during the poster sessiat the upcoming SITC Annual Meeting 2022。 -
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb 10/27/2022 Obsidian Therapeutics,Inc.today announced that Bristol Myers Squibb cer CD40L。 -
FDA Weekly Review looks at the FDA's actions related to drug approvals,IND approvals,designations and more.Here’salook at what happened this week。 -
D Anderson and Obsidian Therapeutics announce FDA Clearance of IND application for novel TIL therapy OBX-115 7/21/2022 The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics,Inc.today announced Food and Drug Administration(FDA)clearance of an Investigational New Drug(IND)application foran MD Andersonsored Phase I clinical study of OBX-115,Obsidian's lead engineed turmolethery y candidate。 -
Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE®Technology at the American Society of Gene and Cell Therapy(ASGCT)Annual Meeting 2022 5/17/2022 Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE®Technology at the American Society of Gene and Cell Therapy(ASGCT)Annual Meeting 2022。 -
Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™Program at the American Associate of Cancer Research(AACR)Annual Meeting 2022 4/11/2022 Obsidian Therapeutics,Inc.preclinical data high lighting its cytoTIL15™program during a poster session at the upcoming AACR Annual Meeting 2022。 -
Obsidian Therapeutics Appoints Maria Fardis,Ph.D.,as Chair of its Board of Directors 1/19/2022 Obsidian Therapeutics,Inc.today announced that Maria Fardis,Ph.D.,has assumed the role of Chair of Obsidian's Board of Directors。 -
As BioSpace proudly introduces our2022 Hotbed Maps,let’s explore the industry’s most thriving territories,research leading employers and search for relevant jobs on BioSpace。 -
BioSpace is marking Martin Luther King,Jr.Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality。 -
Precision Gene Therapy on the Cusp 1/11/2022 The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date:the risk of unintended consequences。